Loading...
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England
Fox, C. P. Townsend, W. Gribben, J. G. Menne, T. Kalakonda, N. Williams, P. Toron, F. Tyas, E. Cooper, M. Rickards, J.
Fox, C. P.
Townsend, W.
Gribben, J. G.
Menne, T.
Kalakonda, N.
Williams, P.
Toron, F.
Tyas, E.
Cooper, M.
Rickards, J.
Citations
Altmetric:
Abstract
Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Article
Citation
Fox CP, Townsend W, Gribben JG, Menne T, Kalakonda N, Williams P, et al. Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England. EJHaem. 2024 Oct;5(5):992-7. PubMed PMID: 39415902. Pubmed Central PMCID: PMC11474359. Epub 2024/10/17. eng.